Arcus Biosciences Inc. (RCUS) stock soared 13.38% on Wednesday in pre-market trading hours. The biopharmaceutical company's shares were boosted by multiple analyst upgrades and increased price targets.
Barclays analyst Peter Lawson maintained a Buy rating on Arcus and set a price target of $29.00. HC Wainwright also upgraded Arcus to Buy from Neutral and raised their price target to $24 from $18, citing the company's strong pipeline and growth prospects.
According to analysts surveyed by FactSet, Arcus currently has an average Buy rating and a mean price target of $31.30, suggesting further upside potential for the stock.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。